MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) and Hansoh Pharma, a Chinese biopharmaceutical company, today announced that they have entered into an exclusive global license agreement for HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist. Read more.